Literature DB >> 2809004

Spontaneous coronary artery spasm in variant angina is caused by a local hyperreactivity to a generalized constrictor stimulus.

J C Kaski1, A Maseri, M Vejar, F Crea, D Hackett.   

Abstract

To assess whether spontaneous coronary artery spasm in patients with variant angina results from local coronary hyperreactivity to a generalized constrictor stimulus or from a stimulus generated only at the site of the hyperreactive segment, the behavior of spastic and nonspastic coronary segments was studied in six patients with variant angina in whom focal coronary spasm developed spontaneously during cardiac catheterization. None of the patients had critical (greater than 50% luminal diameter reduction) organic coronary stenoses. Coronary diameters were measured by computerized quantitative arteriography during control, spontaneous spasm and ergonovine-induced spasm and after intracoronary nitrates were given. During spontaneous spasm, the luminal diameter of spastic and both proximal and distal nonspastic coronary segments was significantly reduced from control values, 64.2%, 13.2% and 14.8%, respectively. Average diameter reduction of unrelated arteries was 12.3%. Ergonovine, which was also administered to four patients, provoked focal spasm at the same site as spontaneous spasm. During intravenous ergonovine, luminal diameter of spastic segments was reduced by 91.5%, that of nonspastic proximal segments by 17.8% and that of nonspastic distal segments by 11.5%. Luminal diameter of unrelated arteries during ergonovine-induced spasm was reduced by 17.7%. Constriction of spastic segments was greater during ergonovine-induced spasm (p less than 0.05), whereas the extent of diameter reduction of nonspastic segments was not significantly different during spontaneous spasm and ergonovine-induced spasm. Intracoronary isosorbide dinitrate dilated spastic and nonspastic coronary segments to a similar extent from control (20.7%, 18% and 16.5%, respectively; p = NS).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2809004     DOI: 10.1016/0735-1097(89)90382-3

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  29 in total

1.  Coronary Artery Spasm.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  2000-02

Review 2.  Provocative testing for coronary reactivity and spasm.

Authors:  Melody Zaya; Puja K Mehta; C Noel Bairey Merz
Journal:  J Am Coll Cardiol       Date:  2013-11-06       Impact factor: 24.094

3.  Relation of basal coronary tone and vasospastic activity in patients with variant angina.

Authors:  Y Ozaki; D Keane; P W Serruys
Journal:  Heart       Date:  1996-03       Impact factor: 5.994

Review 4.  Prinzmetal's variant angina.

Authors:  S Mayer; L D Hillis
Journal:  Clin Cardiol       Date:  1998-04       Impact factor: 2.882

5.  Coronary artery spasm as a cause of angina.

Authors:  Scott Kinlay
Journal:  Circulation       Date:  2014-02-26       Impact factor: 29.690

6.  Variant angina in an adolescent.

Authors:  D Ivy; J Kaye; D Flitter; J Wiggins
Journal:  Pediatr Cardiol       Date:  1994 Jan-Feb       Impact factor: 1.655

Review 7.  Variant Angina and Aborted Sudden Cardiac Death.

Authors:  Amartya Kundu; Aditya Vaze; Partha Sardar; Ahmed Nagy; Wilbert S Aronow; Naomi F Botkin
Journal:  Curr Cardiol Rep       Date:  2018-03-08       Impact factor: 2.931

8.  Trazodone overdose-induced Prinzmetal's angina pectoris.

Authors:  Bhesh Raj Karki; Paritosh Prasai; Asim Ruhela; Yub Raj Sedhai
Journal:  Proc (Bayl Univ Med Cent)       Date:  2019-09-25

9.  Mechanisms of ergonovine-induced hyperconstriction of coronary artery after x-ray irradiation in pigs.

Authors:  S Egashira; W Mitsuoka; H Tagawa; T Kuga; H Tomoike; M Nakamura; A Takeshita
Journal:  Basic Res Cardiol       Date:  1995 Mar-Apr       Impact factor: 17.165

Review 10.  Management of vasospastic angina--role of nicorandil.

Authors:  J C Kaski
Journal:  Cardiovasc Drugs Ther       Date:  1995-03       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.